Reported about 9 hours ago
Pfizer has announced its acquisition of Metsera for $4.9 billion, as part of its strategy to strengthen its position in the weight loss treatment market with long-lasting GLP-1 receptor agonists. The deal includes a premium on Metsera's share price and potential additional payments dependent on clinical milestones. With this purchase, Pfizer gains access to four clinical-stage programs, enhancing its competitive edge against firms like Novo Nordisk and Eli Lilly, while addressing the growing demand in the obesity treatment sector.
Source: YAHOO